Clinical trials: Age Related Maculopathy
Age-Related Macular Degeneration, Choroidal Neovascularization
Stratus Versus Cirrus OCT in AMD
The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time.
- Trial name
- NCT00568191
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Age-Related Macular Degeneration, Diabetic Retinopathy
National Eye Institute Biorepository for Retinal Diseases
Background: To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time.
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease
- Trial name
- NCT01496625
- Where
- United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Beovu Experience UZ Leuven
Reporting early real-world clinical data of consecutive patients on the use of Beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.
- Trial name
- BEL (NCT05220085)
- Testing
- Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Neovascular Age-related Macular Degeneration
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
The study will enroll up to 30 AMD patients diagnosed with NV-AMD in at least one eye at the time of enrollment. At the Study Visit, fluid must be present in at least one eye of the subjects.
- Trial name
- NCT05281042
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Notal Vision Inc.
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.
- Trial name
- ARCHER (NCT04656561)
- Testing
- ANX007
- Where
- 53 sites in United States, Australia and 1 more
- Volunteers
- 270 people
- Sponsor
- Annexon, Inc.
Age-Related Macular Degeneration
Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora
Ranibizumab (Lucentis) is currently the best treatment for wet Age-Related Macular Degeneration (AMD). To work, the drug must be injected by means of an intravitreal injection (IVT) into the vitreous (jelly-like material) cavity…
- Trial name
- NCT01577342
- Testing
- Moxifloxacin 0.5%
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Normal Eyes, Age Related Macular Degeneration
High Resolution Imaging OCT Study
The goal of this pilot study is to compare image quality between the investigational devices (R1 and HighRes OCT) and the SPECTRALIS (cleared) in adult participants with normal and/or pathology eyes.
- Conditions
- Normal Eyes, Age Related Macular Degeneration, Diabetic Retinopathy, Eyes With Retinal Diseases
- Trial name
- NCT07338461
- Testing
- Autofluorescence Imaging, Infrared reflectance imaging, OCT imaging
- Where
- Italy
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Dry Age-related Macular Degeneration
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular…
- Trial name
- CORD-IV (NCT05706896)
- Testing
- Intravitreal injection of CB-PRP
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Age-Related Macular Degeneration
Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration Patients
The aim of this study is to evaluate the quality of life of AMD patients related to vision using the short version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), patients' social support, and their…
- Trial name
- NCT05427994
- Testing
- National Eye Institute Visual Function Questionnaire
- Where
- 2 sites in Kazakhstan
- Volunteers
- 458 people
- Sponsor
- Asfendiyarov Kazakh National Medical University
Age-related Macular Degeneration
Reticular Pseudodrusen Progression Study
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. Reticular pseudodrusen (RPD) have been recognized as an additional phenotypic characteristic frequently observed in…
- Trial name
- NCT02345317
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Muenster
Wet Age-related Macular Degeneration (wAMD)
Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）
This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner.
- Trial name
- NCT03054818
- Where
- 49 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Macular Degeneration
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary…
- Trial name
- NCT00090623
- Testing
- rhuFab V2 (ranibizumab)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Genentech, Inc.
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa
- Trial name
- NCT01736059
- Testing
- CD34+ bone marrow stem cells intravitreal
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Macular Degeneration
High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration
This study will use an eye imaging test called high speed indocyanine green angiography (HS-ICG), which examines leaky vessels in the eye, to try to find out why individuals respond differently to ranibizumab (Lucentis) treatment…
- Trial name
- NCT00656903
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age Related Macular Degeneration
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A study to use in home technology to reduce the burden of in office visits and injections.
- Trial name
- Liberty (NCT01863199)
- Testing
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Retinal Consultants of Arizona
Wet Age-related Macular Degeneration
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in subjects with refractory wet age-related macular degeneration (wAMD).
- Trial name
- NCT03558074
- Testing
- ALK4290
- Where
- 5 sites in Hungary
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Macular Degeneration, Senile, Laser Burn of Retina
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.
- Conditions
- Macular Degeneration, Senile, Laser Burn of Retina, Macular Degeneration Intermediate, Macular Degeneration, Dry
- Trial name
- PASCAL-RPD (NCT04847635)
- Testing
- Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale San Raffaele
Age Related Macular Degeneration
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD.
- Trial name
- TEMPURA (NCT04895293)
- Testing
- RBM-007 Injectable Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Stereotactic Radiotherapy for Wet AMD (STAR)
This study investigates the use of radiation to treat wet age-related macular degeneration (AMD). The radiation is delivered using a robotically controlled device that projects overlapping beams of radiation onto the macula, the…
- Trial name
- STAR (NCT02243878)
- Testing
- 0.5 mg ranibizumab
- Where
- 30 sites in United Kingdom
- Volunteers
- 411 people
- Sponsor
- King's College Hospital NHS Trust
Dry Eye Syndromes, Age-Related Macular Degeneration
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
The purpose of this study is to determine increases in the Omega Index test indicating optimal Omega-3s particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels for overall systemic benefits including…
- Conditions
- Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
- Trial name
- NCT05763940
- Testing
- OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Western University of Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.